# BioReason-Pro SFT Review: F2rl2 (Mus musculus)

Source: F2rl2-deep-research-bioreason-sft.md

- **Correctness**: 3/5
- **Completeness**: 2/5

## Functional Summary Review

The BioReason functional summary describes F2rl2 as:

> A multi-pass plasma membrane receptor in mouse that is activated by proteolytic cleavage of its N-terminus, exposing a tethered activation peptide that turns on a rhodopsin-like signaling core. Upon activation, it couples to heterotrimeric G proteins to stimulate phospholipase C, mobilize intracellular calcium, regulate ion channels, and activate protein kinase C and tyrosine kinases. These signaling outputs modulate epithelial and endocrine physiology, including enhancing insulin secretion and shaping responses to luminal proteases at the apical surface, with timing and amplitude tuned by associated GTPase-accelerating regulators and crosstalk with related protease-activated receptors.

This summary captures the general signaling framework of a protease-activated receptor but misses the most distinctive and well-characterized feature of mouse PAR3.

**Correctness issues:**

1. **The most critical omission is the cofactor function.** Mouse PAR3 does NOT independently mediate transmembrane signaling in platelets. Instead, it functions as a cofactor that binds thrombin and presents it to PAR4 for productive cleavage and activation (PMID:10766244, [DOI](https://doi.org/10.1038/35007085)). This is the single most important and species-specific feature of mouse PAR3, established by the Coughlin lab in a Nature paper. The BioReason summary treats mouse PAR3 as a conventional signaling GPCR, which is incorrect for its best-characterized biological context (platelets).

2. **GTPase activator activity (GO:0005096) is not supported.** The thinking trace claims PAR3 exerts "GTPase activator activity via associated RGS proteins." PAR3 is not an RGS protein and does not have GTPase activator activity. The presence of RGS proteins in the signaling cascade does not confer this activity to the receptor itself. This is an over-annotation by attribution of pathway-level activities to the receptor.

3. **Ion channel regulator activity (GO:0005246, GO:0099108) is speculative.** The thinking trace attributes calcium channel regulator activity and ion channel regulator activity to PAR3. While downstream signaling can affect calcium channels, PAR3 itself is not a channel regulator. The BioReason model conflates downstream pathway effects with intrinsic molecular functions.

4. **Protein tyrosine kinase activator activity (GO:0043535) is speculative.** The claim that PAR3 "directly exhibits protein tyrosine kinase activator activity by engaging receptor-proximal tyrosine kinases such as Src" has no direct experimental support for mouse PAR3 specifically.

5. **The claim about "apical positioning" and "luminal proteases" implies a primarily epithelial function.** While the existing GOA annotation places F2rl2 at the apical plasma membrane (GO:0016324 from PMID:16892058), this annotation is likely erroneous -- PMID:16892058 studies the cell polarity protein PARD3, not the thrombin receptor F2rl2/PAR3. The two proteins share the name "Par3" but are entirely different genes (Pard3 vs F2rl2).

6. **"Phospholipase C activator activity" and "protein kinase C activator activity"** are GO terms that describe specific molecular activities, not pathway outcomes. PAR3 does not directly activate PLC -- it couples to Gq, which then activates PLC. The BioReason model conflates signaling pathway effects with direct molecular function.

**Completeness issues:**

1. **No mention of the cofactor function for PAR4.** The defining feature of mouse PAR3 -- that it binds thrombin and facilitates cleavage of PAR4 without signaling independently (PMID:10766244) -- is completely absent. This is the most important insight about this protein from the last 25 years of research.

2. **No mention of the PAR3 knockout phenotype.** Par3-/- mice are protected against thrombosis (PMID:12384423, [DOI](https://doi.org/10.1182/blood-2002-05-1470)), a key in vivo validation of PAR3 function.

3. **No mention of PAR3-PAR4 dimerization.** PAR3 forms constitutive homodimers and heterodimers with PAR4, and negatively regulates PAR4-mediated calcium mobilization and PKC activation (PMID:23405206, [DOI](https://doi.org/10.1371/journal.pone.0055740)). This dual role -- cofactor at low thrombin, negative regulator of signaling amplitude -- is absent.

4. **No mention of the species-specific difference.** Human PAR3 can signal directly, but mouse PAR3 cannot signal independently in platelets. This is a crucial biological distinction that the BioReason model ignores by treating PAR3 generically.

5. **No platelet biology context.** The primary documented biological context for mouse PAR3 is platelet activation and hemostasis. The BioReason summary emphasizes epithelial and endocrine biology while omitting the platelet context entirely.

## Comparison with InterPro2GO

The InterPro2GO annotations are:
- GO:0004930 G protein-coupled receptor activity (from IPR000276, rhodopsin-like GPCR)
- GO:0007186 G protein-coupled receptor signaling pathway (from IPR000276)
- GO:0015057 thrombin-activated receptor activity (from IPR003912/IPR003943)
- GO:0007596 blood coagulation (from IPR003912/IPR003943)
- GO:0070493 thrombin-activated receptor signaling pathway (from IPR003912/IPR003943)
- GO:0016020 membrane (from IPR000276/IPR003912/IPR003943/IPR017452)

The BioReason narrative adds mechanistic detail (PLC activation, calcium mobilization, insulin secretion) that goes beyond raw InterPro2GO mappings. However, it also introduces unsupported molecular function predictions (GTPase activator activity, ion channel regulator activity, protein tyrosine kinase activator activity) and misses the cofactor function that is the most distinctive feature of mouse PAR3. The InterPro2GO annotations are more conservative but more accurate.

## Notes on Thinking Trace

The thinking trace methodically dissects domain architecture but reveals several critical weaknesses:

1. **Pure domain-based reasoning fails to capture cofactor biology.** The trace reasons that PAR3's 7TM core "supports G protein activation" -- which is structurally correct but functionally misleading for mouse PAR3, whose 7TM domain does not couple to G proteins in platelets. The cofactor function cannot be predicted from domain architecture alone.

2. **Over-attribution of pathway activities to the receptor.** The trace attributes GTPase activator activity, PLC activator activity, PKC activator activity, and ion channel regulator activity to PAR3 based on the downstream signaling cascade. This conflates pathway membership with intrinsic molecular function -- a common error in function prediction.

3. **No GO term predictions were generated** in the "GO Term Predictions" section, despite the elaborate thinking trace. The BioReason model produced an extensive functional narrative but failed to translate it into specific GO predictions, which is the stated purpose of the tool.

4. **The UniProt summary used by BioReason is incomplete.** It states "Receptor for trypsin" without mentioning the thrombin cofactor function, leading the model to rely entirely on domain-based reasoning rather than protein-specific biology.

The BioReason prediction demonstrates the limitations of domain-architecture-only reasoning for proteins whose function diverges from the family paradigm. Mouse PAR3's cofactor function for PAR4 cannot be inferred from domains alone and requires organism-specific, gene-specific literature knowledge.
